Skip to Content

'
Richard L. Theriault

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Pregnancy and breast cancer.

Diagnosis and management of bone metastasis.

Cancer care guidelines.

Health service research and outcomes analyses.

Education & Training

Degree-Granting Education

1998 The University of Houston, Houston, TX, MBA, Business Administration
1973 Kirksville College of Osteopathic Medicine, KCOM, Kirksville, MO, DO, Osteopathic Medicine
1970 Truman State University, Kirksville, MO, BS, Biology

Postgraduate Training

7/1983-6/1985 Fellow, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Gabriel N. Hortobagyi
7/1976-6/1977 Residency, Internal Medicine, Oklahoma Osteopathic Hospital, Tulsa, OK, Dr. Richard C. Stabb
7/1974-6/1976 Residency, Internal Medicine, Normandy Osteopathic Hospital, St. Louis, MO, Dr. Thomas J. Stees
7/1973-6/1974 Rotating Internship, Normandy Osteopathic Hospital, St. Louis, MO, Dr. Robert Owen

Board Certifications

1986 American Osteopathic Board of Internal Medicine - Oncology
1980 American Osteopathic Board of Internal Medicine - Internal Medicine

Experience/Service

Institutional Committee Activities

Chairman, Institutional Review Board 2, 2003-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis. e-Pub 6/1/2010. PMID: 20519803.
2. Morrow PK, Tarrand JJ, Taylor SH, Kau SW, Theriault RL, Hortobagyi GN, Broglio KR, Hahn KM. Effects of chronic hepatitis C infection on the treatment of breast cancer patients. Ann Oncol 21(6):1233-6, 6/2010. e-Pub 10/29/2009. PMID: 19875760.
3. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 102(4):651-7, 2/16/2010. e-Pub 1/26/2010. PMCID: PMC2837571.
4. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault R, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953-8, 12/2009. e-Pub 7/12/2009. PMCID: PMC2791352.
5. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6):606-14, 6/2009. PMID: 19482249.
6. Elting LS, Cooksley CD, Bekele BN, Giordano SH, Shih YC, Lovell KK, Avritscher EB, Theriault R. Mammography Capacity Impact on Screening Rates and Breast Cancer Stage at Diagnosis. Am J Prev Med 37(2):102-108, 2009. PMID: 19524392.
7. Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. J Clin Oncol 26(34):5553-60, 12/2008. e-Pub 10/2008. PMID: 18955448.
8. Hassett MJ, Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC. Selecting high priority quality measures for breast cancer quality improvement. Med Care 46(8):762-70, 8/2008. PMID: 18665055.
9. Punglia RS, Hughes ME, Edge SB, Theriault RL, Bookman MA, Wilson JL, Ottesen RA, Niland JC, Weeks JC. Factors Associated with Guideline-Concordant Use of Radiotherapy After Mastectomy in the National Comprehensive Cancer Network. Int J Radiat Oncol Biol Phys 72(5):1434-1440, 2008. e-Pub 5/2008. PMID: 18472360.
10. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive Breast Cancer. J Natl Compr Canc Netw 3(3):246-312, 3/2007. PMID: 17439758.
11. Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, Yang W, Perkins G, Hortobagyi GN, Theriault RL. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219-26, 9/2006. PMID: 16894524.
12. Morrow PK, Theriault RL. Pregnancy after the diagnosis of breast cancer. Clin Breast Cancer 7(2):173-5, 6/2006. PMID: 16800981.
13. Yang WT, Dryden MJ, Gwyn K, Whitman GJ, Theriault R. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 239:52-60, 4/2006. PMID: 16484353.
14. Christian CK, Niland J, Edge SB, Ottesen RA, Hughes ME, Theriault R, Wilson J, Hergrueter CA, Weeks JC. A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg 243:241-9, 2/2006. PMID: 16432358.
15. Loibl S, von Minckwitz G, Gwyn K, Ellis P, Blohmer JU, Schlegelberger B, Keller M, Harder S, Theriault RL, Crivellari D, Klingebiel T, Louwen F, Kaufmann M. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 106(2):237-46, 1/2006. PMID: 16342247.
16. Buchholz TA, Theriault RL, Niland JC, Hughes ME, Ottesen R, Edge SB, Bookman MA, Weeks JC. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers. J Clin Oncol 24(3):361-9, 1/2006. PMID: 16421417.
17. Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6(4):354-6, 10/2005. PMID: 16277887.
18. Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol 23:783-91, 2/2005. PMID: 15681522.
19. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema DF, Feuer EJ, Theriault RL. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784-1792, 2005.
20. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung B-M, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology. J Natl Comp Cancer Network 3:238-289, 2005.
21. Gonzalez-Angulo AM, Walters RS, Carpenter RJ, Jr, Ross MI, Perkins GH, Gwyn K, Theriault RL. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 5:317-9, 10/2004. PMID: 15507181.
22. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292-9, 6/2004. PMID: 15160331.
23. Edge SB, Niland JC, Bookman MA, Theriault RL, Ottesen R, Lepisto E, Weeks JC. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 95:1514-21, 10/2003. PMID: 14559873.
24. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98:1055-60, 9/2003. PMID: 12942575.
25. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, Singletary SE, Theriault RL, Hortobagyi GN, Hunt KK, Buchholz TA. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244-8, 9/2003. PMID: 12947058.
26. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 97:2716-23, 6/2003. PMID: 12767083.
27. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97:2960-71, 6/2003. PMID: 12784330.
28. Theriault RL. Zoledronic acid (Zometa) use in bone disease. Expert Rev Anticancer Ther 3:157-66, 4/2003. PMID: 12722875.
29. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8:3360-8, 11/2002. PMID: 12429622.
30. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL. Estrogen replacement therapy (ERT) for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95:1817-26, 11/2002. PMID: 12404273.
31. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-36, 9/2002. PMID: 12202663.
32. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-9, 5/2002. PMID: 12006521.
33. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-44, 5/2002. PMID: 12006516.
34. Kuerer HM, Gwyn K, Ames FC, Theriault RL. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 131(1):108-10, 2002. PMID: 11812971.
35. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 8(1):2-9, Jan-Feb, 2002. PMID: 11856154.
36. Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, Ames FC, Buchholz TA, Sahin AA, Kuerer HM. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 194(1):54-64, 2002. PMID: 11800340.
37. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 92:2523-8, 11/2001. PMID: 11745185.
38. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24:421-4, 8/2001. PMID: 11474279.
39. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19:3422-33, 7/2001. PMID: 11454891.
40. Katz A, Strom EA, Buchholz TA, Theriault R, Singletary SE, McNeese MD. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50:735-42, 7/2001. PMID: 11395242.
41. Katz A, Buchholz TA, Thames H, Smith CD, McNeese MD, Theriault R, Singletary SE, Strom EA. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. Int J Radiat Oncol Biol Phys 50:397-403, 6/2001. PMID: 11380226.
42. Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 19:2002-9, 4/2001. PMID: 11283133.
43. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Jr, Hortobagyi GN. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716-22, 3/2001. PMID: 11251001.
44. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, 3rd, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19:459-66, 2001. PMID: 11458813.
45. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082-90, 3/2000. PMID: 10699899.
46. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Multidisciplinary management of breast cancer during pregnancy: An 8 year experience using a standardized protocol. J Clin Oncol 17:855-61, 3/1999. PMID: 10071276.
47. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17:846-54, 3/1999. PMID: 10071275.
48. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34(13):2021-6, 12/1998. PMID: 10070304.
49. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038-44, 6/1998. PMID: 9626201.
50. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335(24):1785-91, 12/1996. PMID: 8965890.

Invited Articles
1. Theriault RL. Bisphosphonates: ready for use as adjuvant therapy of breast cancer? Curr Opin Obstet Gynecol 22(1):61-6, 2/2010. e-Pub 11/2009. PMID: 19934757.
2. Theriault R, Hahn K. Management of Breast Cancer in Pregnancy. Curr Oncol Rep 9:17-21, 1/2007.
3. Theriault RL. Strategies to prevent chemotherapy-induced bone loss in women with breast cancer. Clin Breast Cancer 5 Suppl:S63-70, 2/2005. PMID: 15807926.

Last updated: 3/8/2013